Methyl p-hydroxybenzoate


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0000084 Mitotic s phase Increases phenotype PMID:29846718; PMID:31745603; PMID:33358972
GO:0000086 G2/m transition of mitotic cell cycle Affects phenotype PMID:31745603
GO:0001541 Ovarian follicle development Decreases phenotype PMID:22777679; PMID:28208728
GO:0003401 Axis elongation Increases phenotype PMID:28927898
GO:0006915 Apoptotic process Affects phenotype PMID:17186576; PMID:29846718; PMID:31745603; PMID:35174924
GO:0006950 Response to stress Increases phenotype PMID:23727995
GO:0008283 Cell population proliferation Increases phenotype PMID:17186576; PMID:23744433; PMID:23744433; PMID:24481588; PMID:27581495; PMID:24481588; PMID:27581495; PMID:33358972
GO:0008380 Rna splicing Affects phenotype PMID:31745603
GO:0010424 Dna methylation on cytosine within a cg sequence Affects phenotype PMID:34523531
GO:0016049 Cell growth Affects phenotype PMID:17121429; PMID:36277366
GO:0022414 Reproductive process Decreases phenotype PMID:27286252
GO:0032332 Positive regulation of chondrocyte differentiation Increases phenotype PMID:28527915
GO:0032964 Collagen biosynthetic process Decreases phenotype PMID:28382686
GO:0035938 Estradiol secretion Affects phenotype PMID:35174924
GO:0042310 Vasoconstriction Decreases phenotype PMID:2868457
GO:0042311 Vasodilation Increases phenotype PMID:2868457
GO:0044237 Cellular metabolic process Increases phenotype PMID:28382686; PMID:31745603; PMID:32055740; PMID:35174924; PMID:36277366; PMID:37690743
GO:0045023 G0 to g1 transition Affects phenotype PMID:31745603
GO:0045333 Cellular respiration Affects phenotype PMID:33140513
GO:0045444 Fat cell differentiation Increases phenotype PMID:24155963
GO:0045600 Positive regulation of fat cell differentiation Increases phenotype PMID:28527915
GO:0045669 Positive regulation of osteoblast differentiation Increases phenotype PMID:28527915
GO:0045930 Negative regulation of mitotic cell cycle Affects phenotype PMID:31745603
GO:0046884 Follicle-stimulating hormone secretion Increases phenotype PMID:28208728
GO:0048160 Primary follicle stage Affects phenotype PMID:22777679
GO:0048598 Embryonic morphogenesis Affects phenotype PMID:28927898
GO:0070265 Necrotic cell death Increases phenotype PMID:17186576; PMID:31745603
GO:0070374 Positive regulation of erk1 and erk2 cascade Increases phenotype PMID:26253279
GO:0070994 Detection of oxidative stress Affects phenotype PMID:35174924
GO:0071897 Dna biosynthetic process Decreases phenotype PMID:28382686
GO:0072593 Reactive oxygen species metabolic process Affects phenotype PMID:23068419; PMID:24625398
GO:0090398 Cellular senescence Increases phenotype PMID:17186576
GO:1903047 Mitotic cell cycle process Affects phenotype PMID:33358972
GO:2000609 Regulation of thyroid hormone generation Affects phenotype PMID:32464474
GO:2000612 Regulation of thyroid-stimulating hormone secretion Affects phenotype PMID:32283359
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.